As such, FDA-approved drugs that activate PPARγ are highly effective for treating type-2 diabetes in the form of the thiazolidinediones (TZDs) pioglitazone (ActosTM) and rosiglitazone (AvandiaTM; GlaxoSmithKline plc., Brentford, United Kingdom). This evidence concerns the gene PPARG and type 2 diabetes mellitus.